Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A pediatric oncology group phase II study
- 1 March 1993
- Vol. 71 (5), 1898-1903
- https://doi.org/10.1002/1097-0142(19930301)71:5<1898::aid-cncr2820710529>3.0.co;2-q
Abstract
Background. The prognosis for children with recurrent or resistant malignant solid tumors remains dismal. More effective rescue therapy is needed for these children. Methods. Between August 1987 and November 1990, 311 children with recurrent or resistant malignant solid tumors were treated by investigators in the Pediatric Oncology Group with intravenous infusions of 2.0 g/m2 of ifosfamide and 100 mg/m2 of etoposide (VP-16) plus mesna as uroprotection three times daily, with courses being repeated every 14–21 days for as long as the patients responded to therapy. Results. Seventy-four percent of the 294 assessable patients entered in the study had metastatic disease and previously had been treated heavily. The complete response/partial response rate was 30%, and the overall response rate was 39.5%. Toxic effects included nephrotoxicity, mild liver dysfunction, neurotoxicity, and myelosuppression. Sixty-eight percent had an absolute neutrophil count (ANC) of less than 500/μl. In 1606 courses of therapy administered, only 3.6% of patients developed a bacterial infection. Only two patients died of gram-negative sepsis. Four percent of the patients had gross hematuria (> 50 erythrocytes/high-power field), and 18.5% had microscopic hematuria (< 20 erythrocytes/high-power field). Fanconi syndrome developed in eight children. Conclusions. Ifosfamide/VP-16 is an active combination in children with recurrent malignant solid tumors. Although it was myelosuppressive, the incidence of infection was quite low (3.6%). Mesna was very effective in preventing the development of hematuria.Keywords
This publication has 10 references indexed in Scilit:
- Ifosfamide, Fanconi's syndrome, and rickets.Journal of Clinical Oncology, 1991
- Phase II Study of Ifosfamide-Etoposide-Mesna in Adults With Advanced Nonosseous SarcomasJNCI Journal of the National Cancer Institute, 1989
- Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.Journal of Clinical Oncology, 1989
- Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumorsInvestigational New Drugs, 1988
- Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.Journal of Clinical Oncology, 1987
- A phase II study of ifosfamide in the treatment of recurrent sarcomas in young peopleCancer Chemotherapy and Pharmacology, 1986
- Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patientsCancer Treatment Reviews, 1983
- High-dose ifosfamide and mesna as continuous infusion over five days—a phase I/II trialCancer Treatment Reviews, 1983
- High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcomaCancer Treatment Reviews, 1983
- Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapyCancer Treatment Reviews, 1983